Dirk Arnold, MD, director of the University Cancer Center Hamburg at the University Medical Center Hamburg-Eppendorf, in Germany, discusses results of a phase III randomized trial that continued bevacizumab (Avastin) plus standard chemotherapy into the second-line for patients with metastatic colorectal cancer (mCRC). To find out more, visit http://www.onclive.com/onclive-tv/Dr-...